Form D · Biotechnology

SERAPH BIOSCIENCES, INC.

Detroit, MI · CIK 0001697736

Offering snapshot reported Aug 23, 2021 · SEC filing

Reported sold
$7.02M
Offering amount: $7.2M
Investors reported
Not reported
Form D · investor count
Minimum accepted
Not reported
Reported outside-investor minimum
First sale
Not reported
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 23, 2021Amendment$7,022,000No comparisonNot reportedSEC filing
Jun 24, 2020Initial$1,912,884No comparison18SEC filing
Jan 7, 2019Initial$1,526,988No comparison15SEC filing
Feb 15, 2017Initial$1,500,000No comparison1SEC filing

Offering details

Securities
Not reported
Exemptions
Not reported
Duration over one year
Not reported
Business combination
Not reported
Sales commissions
Not reported
Finders' fees
Not reported
Form D file number
021-369574

Source: Form D, filed Aug 23, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Gregory Auner Director
Richard Creager Director
Matthew Cullen Director
Paul Glantz Director
Ahmad Nadeem Ishaque Director
Gary Loveman Director
James Mault Director
Scott Merz Director
Braden Robison Executive
James Shanley Executive
Charles Shanley Director
Michael Shields Director
Mark Trexler Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1001 Woodward Avenue Suite 500
Detroit, MI, 48226